SC
VKTX icon

Shay Capital’s Viking Therapeutics VKTX Stock Holding History

Shay Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,000
Closed -$950K – 440
2024
Q3 		$950K Buy
+15,000
New +$880K 0.13% 99

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Shay Capital's VKTX Position: Q1 2026 in Review

Shay Capital opened a new position in Viking Therapeutics (VKTX) in Q1 2026: 16,500 shares worth $537K. The stake represents 0.04% of the portfolio and ranks #262 among its holdings. This is a return to the name: Shay Capital previously reported a position in VKTX as recently as Q2 2025.

Shay Capital first reported a position in VKTX in Q2 2023 and has held it in 8 quarters since. The position peaked at $2.5M in Q2 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Shay Capital held 16,500 shares of Viking Therapeutics worth $537K as of Q1 2026.
  • Viking Therapeutics was a new Shay Capital position in Q1 2026.
  • Viking Therapeutics made up 0.04% of Shay Capital's portfolio in Q1 2026, its #262 holding.
  • Shay Capital first reported a position in Viking Therapeutics in Q2 2023 and has held it in 8 quarters since.
  • Shay Capital's Viking Therapeutics position peaked at $2.5M in Q2 2024.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Shay Capital's 13F filing for Q1 2026, filed 15 May 2026.